Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Pasteur Nets Flu Vaccine Via Acambis Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

Early C. difficile program comes along with $550 million deal.
Advertisement

Related Content

Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With Australia's CSL
Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL
Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL
Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell
Pfizer Taps Into Cytos’ Vaccine Pipeline
First Roche, Then Bristol: Who’s Next?
Sanofi-Aventis To File For Menactra Use In Infants
Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher
Novartis Cements Chiron Buy With Increased Bid
Novartis Cements Chiron Buy With Increased Bid

Topics

Advertisement
UsernamePublicRestriction

Register

PS068145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel